FMP
Liquidia Corporation
LQDA
NASDAQ
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
13.51 USD
-0.17 (-1.26%)
About
ceo
Dr. Roger A. Jeffs Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.liquidia.com
exchange
NASDAQ
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
CIK
0001819576
ISIN
US53635D2027
CUSIP
53635D202
Address
419 Davis Drive
Phone
919 328 4400
Country
US
Employee
145
IPO Date
Jul 26, 2018
Key Executives
